Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by EWG Elevate Inc.

EWG Elevate Inc. increased its stake in shares of Altimmune, Inc. (NASDAQ:ALTFree Report) by 50.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 15,000 shares of the company’s stock after acquiring an additional 5,000 shares during the period. EWG Elevate Inc.’s holdings in Altimmune were worth $169,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Altimmune by 1.2% during the third quarter. Vanguard Group Inc. now owns 3,344,295 shares of the company’s stock worth $8,695,000 after acquiring an additional 38,323 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Altimmune by 90.4% during the third quarter. American Century Companies Inc. now owns 21,264 shares of the company’s stock valued at $55,000 after buying an additional 10,093 shares during the last quarter. Deutsche Bank AG bought a new position in Altimmune in the 3rd quarter worth approximately $79,000. WealthPlan Investment Management LLC acquired a new stake in Altimmune in the 3rd quarter valued at approximately $31,000. Finally, GSA Capital Partners LLP boosted its position in Altimmune by 153.1% during the 3rd quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock worth $1,159,000 after acquiring an additional 269,676 shares during the period. Hedge funds and other institutional investors own 66.99% of the company’s stock.

Altimmune Price Performance

ALT traded down $0.17 on Friday, reaching $9.86. 14,933,438 shares of the company traded hands, compared to its average volume of 6,362,123. The company has a market cap of $529.78 million, a price-to-earnings ratio of -6.40 and a beta of 0.08. The stock’s 50 day moving average price is $10.35 and its 200-day moving average price is $6.25. Altimmune, Inc. has a 52-week low of $2.09 and a 52-week high of $14.84.

Wall Street Analyst Weigh In

A number of research firms recently commented on ALT. B. Riley reiterated a “buy” rating and set a $20.00 price objective on shares of Altimmune in a research note on Tuesday, February 13th. The Goldman Sachs Group assumed coverage on Altimmune in a report on Wednesday, January 24th. They issued a “neutral” rating and a $13.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Altimmune in a report on Friday, December 1st.

Get Our Latest Report on Altimmune

Altimmune Company Profile

(Free Report)

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.

Further Reading

Institutional Ownership by Quarter for Altimmune (NASDAQ:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.